Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
98%
Ulcerative Colitis
65%
Eosinophilic Esophagitis
60%
Gastroesophageal Reflux Disease
49%
Achalasia
39%
High-resolution Manometry
36%
Placebo
33%
Esophagogastric Junction
30%
Functional Lumen Imaging Probe
26%
Endoscopy
26%
Confidence Interval
25%
Reflux
24%
Infliximab
23%
Proton Pump Inhibitors
21%
Clinical Trials
20%
Clinical Remission
18%
Dysphagia
18%
Barrett's Esophagus
18%
Remission
18%
Esophagus
17%
Vedolizumab
16%
Adverse Events
16%
Irritable Bowel Syndrome
16%
Meta-analysis
16%
Randomized Controlled Trial
14%
Systematic Meta-analysis
14%
Colitis
14%
Esophageal Motility Disorders
14%
Chicago Classification
13%
Medical Therapy
12%
Maintenance Therapy
12%
Peroral Endoscopic Myotomy
12%
Adalimumab
11%
Inflammation
11%
Bolus
11%
Moderate to Severe
11%
Colonoscopy
11%
Gastrointestinal Diseases
11%
Quality of Life
11%
Esophageal Pressure Topography
11%
Odds Ratio
11%
Mesalamine
11%
Peristalsis
11%
Endoscopic Remission
10%
Clinical Response
10%
Gastroesophageal Reflux
10%
Clinical Practice
10%
Aminosalicylates
10%
Disease Activity
10%
Pathophysiology
10%
Manometry
10%
Panometry
9%
Endoscopic Surgery
9%
Active Ulcerative Colitis
9%
Corticosteroids
9%
Dysplasia
9%
Induction Therapy
9%
Active Crohn's Disease
9%
Proton Pump Inhibitor Therapy
9%
Lower Esophageal Sphincter
9%
Motility
8%
Microbiota
8%
Hiatal Hernia
8%
United States
8%
Gastroenterology
8%
Gastroenterologist
8%
Esophageal Motility
8%
Upper Esophageal Sphincter
8%
Hospitalization
8%
Crohn's Disease Activity Index
8%
Endoscopic Retrograde Cholangiopancreatography
8%
Endoscopist
8%
Clinical Outcomes
8%
Distensibility
7%
Ustekinumab
7%
Disease Severity
7%
Intestinal Inflammation
7%
Reflux Disease
7%
Randomized Placebo-controlled Trial
7%
Symptom Severity
7%
Adult Patients
7%
Ulcerative Colitis Patient
7%
Heartburn
7%
Stricture
7%
Acid Reflux
7%
Endoscopic Diagnosis
7%
T Helper 17 (Th17)
7%
Cough
7%
Colectomy
7%
Obesity
6%
High-resolution Impedance Manometry
6%
Biological Agents
6%
Eosinophils
6%
Patient-reported Outcomes
6%
Esophagitis
6%
Colon
6%
Diarrhea
6%
Treatment Options
6%
Esophageal Acid Exposure
6%
Medicine and Dentistry
Inflammatory Bowel Disease
63%
Diseases
59%
Eosinophilic Esophagitis
54%
Ulcerative Colitis
54%
Gastroesophageal Reflux
53%
Crohn's Disease
51%
Reflux
44%
Achalasia
43%
High Resolution Manometry
39%
Endoscopy
37%
Sphincter
28%
Esophagus
26%
Plummer-Vinson Syndrome
24%
Manometry
23%
Proton-Pump Inhibitor
22%
Placebo
21%
Combination Therapy
19%
Systematic Review
19%
Clinical Trial
17%
Barrett Esophagus
17%
Esophagus Motility
16%
Adverse Event
16%
Peristalsis
16%
Colonoscopy
15%
Quality of Life
15%
Patient with Inflammatory Bowel Disease
14%
Obstruction
14%
Vedolizumab
13%
Esophageal Motility Disorder
13%
Endoscopic Retrograde Cholangiopancreatography
12%
Patient with Ulcerative Colitis
12%
Randomized Controlled Trial
12%
Disease
12%
Dysplasia
11%
Esophagus Pressure
11%
Colitis
11%
Meta-Analysis
11%
Biopsy Technique
11%
Biological Product
11%
Infliximab
11%
Patient with Crohn's Disease
11%
Health Care Cost
10%
Odds Ratio
10%
Mesalazine
10%
Prevalence
10%
Peroral Endoscopic Myotomy
10%
Hiatus Hernia
10%
Irritable Bowel Syndrome
10%
Disease Activity
10%
Neoplasm
10%
Clinician
9%
Gastroenterology
9%
Myotomy
9%
Pathophysiology
9%
Maintenance Therapy
9%
Eosinophil
8%
Tumor Necrosis Factor
8%
Recurrent Disease
8%
Malignant Neoplasm
8%
Patient-Reported Outcome
8%
Muscle Contractility
8%
Stricture
8%
Colectomy
8%
Cancer
8%
Colorectal Carcinoma
7%
Nissen Fundoplication
7%
Infection
7%
Endoscopic Ultrasound
7%
Colon
7%
Gastrointestinal Disease
7%
Stereotypic Movement Disorder
7%
Post-Hoc Analysis
6%
Biological Marker
6%
Diarrhea
6%
Gut
6%
Biological Therapy
6%
Heartburn
6%
Volunteer
6%
Eosinophilic Gastrointestinal Disorder
6%
Motility Disorder
6%
Diet Therapy
6%
Hypervigilance
5%
Pediatrics
5%
Esophagitis
5%
Gastrointestinal Distress
5%
Constipation
5%
Radiofrequency Ablation
5%
Cohort Analysis
5%
Esophageal Disorder
5%
Colorectal Cancer Screening
5%
Diffuse Esophageal Spasm
5%
Rectal Bleeding
5%
Adalimumab
5%
Antireflux Operation
5%
Eosinophilia
5%